Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: Final report of a prospective clinical trial

Johnny Kao, Chien Ting Chen, Charles C L Tong, Stuart Packer, Myron Schwartz, Shu Hsia Chen, Max W. Sung

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1-28) and SBRT 50 Gy (days 8-12 and 15-19) and maintenance sunitinib was used in 39 % of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 %, 40 %, 34 % and 29 %, respectively. At last follow-up, 26 % of patients were alive without evidence of disease, 7 % were alive with distant metastases, 48 % died from distant metastases, 2 % died from local progression, 13 % died from comorbid illness, and 4 % died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio=0.25, p=0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.

Original languageEnglish (US)
Pages (from-to)145-153
Number of pages9
JournalTargeted Oncology
Volume9
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Radiosurgery
Clinical Trials
Neoplasm Metastasis
Radiotherapy
Survival
Disease-Free Survival
sunitinib
Prostate
Neoplasms
Maintenance
Kidney
Therapeutics

Keywords

  • Image-guided radiation therapy
  • Metastases
  • Oligometastases
  • Stereotactic body radiation therapy (SBRT)
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases : Final report of a prospective clinical trial. / Kao, Johnny; Chen, Chien Ting; Tong, Charles C L; Packer, Stuart; Schwartz, Myron; Chen, Shu Hsia; Sung, Max W.

In: Targeted Oncology, Vol. 9, No. 2, 2014, p. 145-153.

Research output: Contribution to journalArticle

Kao, Johnny ; Chen, Chien Ting ; Tong, Charles C L ; Packer, Stuart ; Schwartz, Myron ; Chen, Shu Hsia ; Sung, Max W. / Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases : Final report of a prospective clinical trial. In: Targeted Oncology. 2014 ; Vol. 9, No. 2. pp. 145-153.
@article{75b480fac1c24ac799edc57a1ae99715,
title = "Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: Final report of a prospective clinical trial",
abstract = "Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1-28) and SBRT 50 Gy (days 8-12 and 15-19) and maintenance sunitinib was used in 39 {\%} of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 {\%}, 40 {\%}, 34 {\%} and 29 {\%}, respectively. At last follow-up, 26 {\%} of patients were alive without evidence of disease, 7 {\%} were alive with distant metastases, 48 {\%} died from distant metastases, 2 {\%} died from local progression, 13 {\%} died from comorbid illness, and 4 {\%} died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio=0.25, p=0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.",
keywords = "Image-guided radiation therapy, Metastases, Oligometastases, Stereotactic body radiation therapy (SBRT), Sunitinib",
author = "Johnny Kao and Chen, {Chien Ting} and Tong, {Charles C L} and Stuart Packer and Myron Schwartz and Chen, {Shu Hsia} and Sung, {Max W.}",
year = "2014",
doi = "10.1007/s11523-013-0280-y",
language = "English (US)",
volume = "9",
pages = "145--153",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "2",

}

TY - JOUR

T1 - Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases

T2 - Final report of a prospective clinical trial

AU - Kao, Johnny

AU - Chen, Chien Ting

AU - Tong, Charles C L

AU - Packer, Stuart

AU - Schwartz, Myron

AU - Chen, Shu Hsia

AU - Sung, Max W.

PY - 2014

Y1 - 2014

N2 - Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1-28) and SBRT 50 Gy (days 8-12 and 15-19) and maintenance sunitinib was used in 39 % of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 %, 40 %, 34 % and 29 %, respectively. At last follow-up, 26 % of patients were alive without evidence of disease, 7 % were alive with distant metastases, 48 % died from distant metastases, 2 % died from local progression, 13 % died from comorbid illness, and 4 % died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio=0.25, p=0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.

AB - Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1-28) and SBRT 50 Gy (days 8-12 and 15-19) and maintenance sunitinib was used in 39 % of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 %, 40 %, 34 % and 29 %, respectively. At last follow-up, 26 % of patients were alive without evidence of disease, 7 % were alive with distant metastases, 48 % died from distant metastases, 2 % died from local progression, 13 % died from comorbid illness, and 4 % died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio=0.25, p=0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.

KW - Image-guided radiation therapy

KW - Metastases

KW - Oligometastases

KW - Stereotactic body radiation therapy (SBRT)

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84902550806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902550806&partnerID=8YFLogxK

U2 - 10.1007/s11523-013-0280-y

DO - 10.1007/s11523-013-0280-y

M3 - Article

C2 - 23660867

AN - SCOPUS:84902550806

VL - 9

SP - 145

EP - 153

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 2

ER -